Bispecific Antibodies Market Revenue to Cross US$ 16.8 billion by 2035

Published: December 2023


According to a recently published report by Roots Analysis, the growing financial burden of chronic disorders, coupled with its impact on mortality rate, has led to an increase in the demand for effective bispecific antibody treatment options.

Bispecific Antibodies Industry Overview

The global bispecific antibodies market is anticipated to grow at a CAGR of 9.5% from 2023-2035, reaching USD 16.8 billion by 2035.

The discovery of the therapeutic potential of monoclonal antibodies and its successful implementation in the treatment of several diseases and biological disorders has revolutionized the pharmaceutical industry. Presently, there are several research efforts being made into engineering antibody therapeutics in order to further improve treatment-related outcomes. A few decades ago, bispecific antibodies were first developed by the incorporation of additional antigen binding sites into monoclonal antibodies. The primary objective of such bivalent molecules has, so far, been to redirect cytotoxic immune effector cells for augmenting the killing of tumor cells by antibodydependent cell-mediated cytotoxicity (ADCC) and other cytotoxic mechanisms mediated by the immune effector cells. This modified form of antibody-based therapeutics is currently gaining a lot of attention from both large and small pharmaceutical companies.

Browse 100+ figures and 170+ market data tables spread across 350+ pages and detailed Table of Content on “Bispecific Antibodies Market, by Therapeutic Area, Mechanism of Action, Target Antigen, Antibody Format, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/bispecific-antibodies/286.html

Market Drivers

Various factors contribute to the market growth of bispecific antibodies market. These include heightened interest and investment, involving innovative research into diverse antibody formats. Advancements in biotechnologies, such as computational modeling and protein engineering techniques, are further expanding the potential for bispecific antibodies. Additionally, pharma companies are increasingly collaborating or acquiring smaller biotech firms to tap into their specialized expertise and technologies to develop bispecific antibodies. In addition, the versatility of bispecific antibodies in addressing complex diseases, including cancer and immune disorders, is amplifying their market demand and research focus.

Market Restraints

One of the primary restraints associated with this industry is regulatory compliance challenges. In most cases, stringent safety and efficacy requirements lead to extended research timelines and higher research costs. Navigating these regulations demands specialized expertise, limiting the growth of small research firms involved in such development efforts. Moreover, manufacturing complexities and cost-intensive production processes are hindering the bispecific antibodies market growth, especially for smaller research organizations.

Growth Factors

Despite the challenges, several growth factors continue to drive the bispecific antibodies market forward. The successful commercialization of several bispecific antibodies, such as Blincyto® and Hemlibra®,  have demonstrated the clinical potential of such therapeutics. Their ability to target multiple pathways or antigens simultaneously presents a promising approach in personalized medicine and combination therapies. Furthermore, advancements in computational tools and high-throughput screening technologies are enhancing antibody design, speeding up discovery, and enabling tailored therapeutics for various diseases, fostering a robust pipeline of candidates for future clinical development.

Bispecific Antibodies Market Segments

Based on therapeutic area, the bispecific antibodies market is segmented into autoimmune disorders, genetic disorders, hematological malignancies, ophthalmic disorders, solid tumors and skin cancers

  • The genetic disorders segment is leading the market, capturing the largest revenue share of 32.1% in 2023.
  • The autoimmune disorders segment is anticipated to show the highest market growth potential during the forecast period of 42.9% annually.

Based on the mechanism of action, the bispecific antibodies market is segmented into cytokines retargeting / neutralization, dual ligands blocking, resistance factors co-targeting, targeting tumor angiogenesis, t-cell retargeting / activation and others

  • The t-cell retargeting / activation segment led the bispecific antibodies market, capturing the largest revenue share of 31.3% in 2023.
  • The cytokines retargeting / neutralization segment is anticipated to show the highest market growth potential during the forecast period of 59.3% annually.

Based on the target antigen, the bispecific antibodies market is segmented into C5-Albumin, CD20 x CD3, CD3 x BCMA, CD3 x CD19, EGFR x cMET, EpCAM x CD3, Factor IXa x Factor X , gp100 x CD3, HER2 x HER2, PD-1 x CTLA-4, PD-L1 x TGFβ, TNF-α x HAS, VEGF x DLL4 and VEGF-A x ANG2

  • The Factor IXa x Factor X segment led the bispecific antibodies market, capturing the largest revenue share of 32.1% in 2023.
  • The PD-1 x CTLA-4 segment is anticipated to show the highest growth potential by growing at a CAGR of 56.5% during the forecast period.

Based on the antibody format, the bispecific antibodies market is segmented into asymmetric and fragments

  • The asymmetric segment led the market, capturing the largest revenue share of 89.4% in 2023.
  • In fact, the asymmetric segment is anticipated to show the highest growth potential among these two formats, by growing at a CAGR of over 3.1% during the forecast period.

Based on the regional insights, the bispecific antibodies market is segmented into North America, Europe, Asia, and Rest of the World

  • North America dominated the bispecific antibodies market and accounted for the largest revenue share of 63.5% in 2023.
  • In Asia, and Rest of the World, the market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The bispecific antibodies market report also includes detailed profiles of key players (listed below) that offer Bispecific Antibodies:

  • Akeso Biopharma
  • Alexion
  • Amgen
  • Genmab
  • Immunocore
  • Janssen Research & Development
  • Linton Pharm
  • Merck
  • OncXerna Therapeutics
  • Pfizer
  • Roche
  • Taisho Pharmaceutical
  • Zymeworks

You Can Download Free Sample PDF Copy of This Report At: 
https://www.rootsanalysis.com/reports/bispecific-antibodies/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry